MedPage Today February 19, 2020
Nicole Lou, Staff Writer

-Quality control, manufacturing capacity loom as obstacles

Gene therapy is finally poised to revolutionize the treatment of many diseases, but the nascent field is facing challenges — notably in manufacturing — that could limit its early success, experts tell MedPage Today.

With two chimeric antigen receptor (CAR) T-cell treatments and two more traditional gene therapies approved, plus a handful of gene therapy products in late-stage trials, excitement is high. But manufacturing bottlenecks, paired with quality control and talent pool concerns, raise questions about the pace of progress.

While there’s “a lot of exciting work” in gene therapy, Kelvin Lee, PhD, director of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), cautioned about what the field can deliver.

“I think...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Precision Medicine, Technology
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article